Based on our findings, we propose that the maintenance of NF-κB activity in T cells could facilitate tumor rejection by supporting T cell effector function, specifically pro-inflammatory cytokine secretion and specific cytotoxicity. This evidence concerns the gene NFKB1 and neoplasm.